HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RCEL
AVITA Medical, Inc.
RCEL lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RCEL Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
RCEL's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RCEL PE Valuation
RCEL has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RCEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
RCEL has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RCEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.17 | +$0.64 |
| Q2 2026 | -$1.43 | +$0.54 |
| Q1 2026 | -$1.56 | +$0.63 |
| Q4 2025 | -$1.74 | +$0.65 |
| Q3 2025 | -$1.81 | +$0.42 |
| Q2 2025 | -$1.97 | -$0.02 |
| Q1 2025 | -$2.19 | -$0.43 |
| Q4 2024 | -$2.39 | -$0.99 |
RCEL has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RCEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RCEL on profitability, with a higher operating margin.
RCEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $26.1M | +53% |
| Q2 2026 | $21.7M | +18% |
| Q1 2026 | $19.3M | +4% |
| Q4 2025 | $17.6M | -4.3% |
| Q3 2025 | $17.1M | -13% |
| Q2 2025 | $18.4M | +21% |
| Q1 2025 | $18.5M | +67% |
| Q4 2024 | $18.4M | +30% |
RCEL's revenue is growing: $26M last quarter, up 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | +44 points |
| Q2 2026 | -32% | +29 points |
| Q1 2026 | -46% | +18 points |
| Q4 2025 | -59% | -5 points |
| Q3 2025 | -54% | +17 points |
| Q2 2025 | -61% | +42 points |
| Q1 2025 | -64% | +91 points |
| Q4 2024 | -54% | +32 points |
RCEL's operating margin was −10% last quarter, up 44 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RCEL on cash generation, producing positive trailing cash flow while its opponent burns cash.
RCEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$821K | +$5.3M |
| Q2 2026 | -$3.6M | +$7.1M |
| Q1 2026 | -$10.1M | +$439K |
| Q4 2025 | -$4.8M | +$4.9M |
| Q3 2025 | -$6.2M | +$4.8M |
| Q2 2025 | -$10.8M | +$4.7M |
| Q1 2025 | -$10.5M | +$11.5M |
| Q4 2024 | -$9.7M | +$1.5M |
RCEL has burned cash in almost every quarter: −$19M over the past year, against −$37M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RCEL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RCEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +116K shares |
| 1 year | +8.7% | +2.5M shares |
| 3 years | +22% | +5.5M shares |
| 5 years | +24% | +6M shares |
| Available history | +65% | +12.1M shares |
RCEL has 31M diluted shares, up 8.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RCEL Net Leverage
RCEL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RCEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.9 | Overbought |
| Stochastic | 86.4 | Overbought |
RCEL's weekly RSI is 80 (overbought) and its Stochastic is 86 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RCEL PE vs Healthcare Sector
RCEL has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RCEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.4 | 13% above |
| 20 week MA | $10.3 | 57% above |
| 50 week MA | $6.62 | 145% above |
| 100 week MA | $6.74 | 140% above |
| 200 week MA | $9.73 | 66% above |
RCEL has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RCEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.7 | $19.0 | -58% |
| 2021 | $19.0 | $12.6 | -34% |
| 2022 | $12.6 | $6.76 | -46% |
| 2023 | $6.76 | $13.7 | +103% |
| 2024 | $13.7 | $13.5 | -1.7% |
| 2025 | $13.5 | $3.44 | -74% |
| 2026 YTD | $3.44 | $16.2 | +371% |
RCEL has the edge over HIMS on returns for 2026, with the stronger performance.